Phase 3 Clinical Trials With Primary Completion Dates in October 2019

This is a list of Phase 3 trials with primary completion dates in October 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
BYSIBeyondSpring, Inc.2019-10-01Phase 3NCT02504489Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
CPRXCatalyst Pharmaceuticals, Inc.2019-10-01Phase 3NCT03304054Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
FOLDAmicus Therapeutics, Inc.2019-10-01Phase 3NCT02194985Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
GBTGlobal Blood Therapeutics, Inc.2019-10-01Phase 3NCT03036813Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
ITRMIterum Therapeutics plc2019-10-01Phase 3NCT03358576Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
ITRMIterum Therapeutics plc2019-10-01Phase 3NCT03357614Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
ITRMIterum Therapeutics plc2019-10-01Phase 3NCT03354598Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
SNYSanofi2019-10-01Phase 3NCT03965962Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults
SNYSanofi2019-10-01Phase 3NCT02992418Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
SUPNSupernus Pharmaceuticals, Inc.2019-10-01Phase 3NCT02618408Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
ZLABZai Lab Limited2019-10-01Phase 3NCT03516084A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer